Jazz Pharmaceuticals Plc Earnings

Jazz Pharmaceuticals Plc’s revenue fell -0.46% since last year same period to $897.84Mn in the Q1 2025. On a quarterly growth basis, Jazz Pharmaceuticals Plc has generated -17.49% fall in its revenue since last 3-months.

Jazz Pharmaceuticals Plc’s net profit fell -533.06% since last year same period to $-92.54Mn in the Q1 2025. On a quarterly growth basis, Jazz Pharmaceuticals Plc has generated -148.42% fall in its net profits since last 3-months.

Jazz Pharmaceuticals Plc’s net profit margin fell -535.98% since last year same period to -10.31% in the Q1 2025. On a quarterly growth basis, Jazz Pharmaceuticals Plc has generated -158.69% fall in its net profit margins since last 3-months.

Jazz Pharmaceuticals Plc’s price-to-earnings ratio after this Q1 2025 earnings stands at 14.98.

Jazz Pharmaceuticals Plc’s earning per share (EPS) estimates for the current quarter stand at 5.09 - a 178.79% jump from last quarter’s estimates.

Jazz Pharmaceuticals Plc’s earning per share (EPS) estimates for the current year stand at 5.09.

Jazz Pharmaceuticals Plc’s earning per share (EPS) fell -100% since last year same period to 0 in the Q3 2025. This indicates that the Jazz Pharmaceuticals Plc has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.